Project Publications
Third Letter of Support – 06/12/2024
MACUSTAR consortium presented the 3-year follow-up data of the clinical study.
EMA supported MACUSTAR with its goals and further research to develop trial enrichment criteria, and trial endpoints for subjects with iAMD.
Find the letter of support here.
Second Letter of Support (15-02-2022)
MACUSTAR requested EMA´s scientific advice on the cross-sectional data, meaning baseline visit data, of the study.
First Letter of Support (15-02-2018)
EMA supported MACUSTAR study design and gave valuable feedback that was further integrated into the study protocol and procedures.
